Stay updated with breaking news from Agvhd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This article will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.
"The findings suggest that early detection and management of vitiligo lesions can be improved by estimating the likelihood of its development in transplant recipients..."
The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.
The panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.
GVHD experts outline the treatment options for patients with steroid-refractory chronic GVHD.